BioSpace News Archive

Apexigen, Inc. a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, announced the presentation of new data from a Phase 2 clinical trial evaluating sotigalimab, Apexigen’s agonist antibody targeting CD40, in combination with neoadjuvant chemoradiation for patients with resectable esophageal and gastroesophageal junction cancers.

Boehringer Ingelheim announced Phase III data from the InPedILD trial, which assessed the pharmacokinetics and safety profile of nintedanib in children and adolescents between 6 and 17 years old with clinically significant fibrosing interstitial lung disease.

Biotimize, a functional growth-stage biotechnology as a service company with a mission to transform lives through biotechnology, announced the opening of a $30 million Series A fundraising round.

Bristol Myers Squibb announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology Congress 2022 from September 9-13 in Paris, France.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, announced positive data from its ongoing Phase 3 study evaluating Clover’s SCB-2019 as a universal COVID-19 booster vaccine candidate.

Clarus Therapeutics Holdings, Inc. announced that it, together with its wholly-owned subsidiary Clarus Therapeutics, Inc., has filed voluntary petitions under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware.